How have RENE shares performed in 2024?

ReNeuron Group's stock was trading at GBX 3.50 at the start of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38. View the best growth stocks for 2024 here .

How were ReNeuron Group's earnings last quarter?

ReNeuron Group plc (LON:RENE) posted its earnings results on Monday, July, 20th. The company reported ($35.90) EPS for the quarter, topping the consensus estimate of ($50.20) by $14.30.

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD) , Sareum (SAR) , ValiRx (VAL) , IOG (IOG) , Dignity (DTY) , Tri-Star Resources plc (TSTR.L) (TSTR) , Sirius Minerals (SXX) , Collagen Solutions plc (COS.L) (COS) , RenovaCare (RCAR) and ReNeuron Group (RNUGF) .

How do I buy shares of ReNeuron Group?

Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:RENE

ReNeuron Group (RENE) Share Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free RENE Stock Alerts

GBX 3.38

-0.08 (-2.17%)

(As of 02/5/2024)

Compare

Today's Range: 3.28
▼
3.50
50-Day Range: 3.38
▼
3.45
52-Week Range: 3.28
▼
11.50

Volume: 177,373 shs
Average Volume: 578,249 shs
Market Capitalization: £1.93 million

P/E Ratio: N/A
Dividend Yield: 0.76%
Price Target: N/A

Stock Analysis Chart Headlines Insider Trades

Get ReNeuron Group alerts:

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About ReNeuron Group Stock (LON:RENE)

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

RENE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RENE Stock News Headlines

April 17, 2024 | lse.co.uk

ReNeuron CFO steps down to pursue other opportunities

April 11, 2024 | americanbankingnews.com

ReNeuron Group (LON:RENE) Shares Pass Above 50-Day Moving Average of $3.40

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 2, 2024 | msn.com

Medtech firm IQ Endoscopes plans to create 100 new jobs and raise millions

March 28, 2024 | lse.co.uk

Upland Resources shares soar as company prepares for Sarawak drilling

March 22, 2024 | msn.com

Company given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administration

March 20, 2024 | lse.co.uk

TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail

February 21, 2024 | morningstar.com

ReNeuron Group PLC RENE

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

February 19, 2024 | lse.co.uk

Trident Royalties secures USD40 million revolving credit facility

February 5, 2024 | lse.co.uk

TRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash return

February 5, 2024 | msn.com

Reneuron issues administration warning as biotech firm puts jobs at risk

November 8, 2023 | lse.co.uk

ReNeuron interim loss narrows on lower costs; eyes partnerships

September 18, 2023 | finance.yahoo.com

ReNeuron Group plc (LON:RENE): Is Breakeven Near?

May 19, 2023 | finance.yahoo.com

ReNeuron Group Slides As Insider Purchases Lose Another UK£75k

May 19, 2023 | finance.yahoo.com

ReNeuron Group Slides As Insider Purchases Lose Another UK£75k \

May 16, 2023 | marketwatch.com

2023 Neuronal Cell Culture Media Market Size and Research Report in Medical Devices & Consumables Sector | with [104 Pages] and Forecast till 2031

May 13, 2023 | marketwatch.com

Global Retinitis Pigmentosa Treatment & Management Market Report 2023-2030: Top Growth Opportunities and Trends

April 27, 2023 | marketwatch.com

Critical Limb Ischemia Drug Market Size by 2031

April 20, 2023 | marketwatch.com

Placental Stem Cell Therapy Market [2023-2030]: Detailed Growth Analysis

April 7, 2023 | marketwatch.com

Stem Cell Therapy Market Size, Revenue, and Forecast 2030

March 28, 2023 | uk.finance.yahoo.com

Global Market for Stem Cells 2023: Potential as Disease Treatment Options Fuels Market Momentum

March 21, 2023 | uk.finance.yahoo.com

Global Market for Stem Cells

March 13, 2023 | proactiveinvestors.com

ReNeuron to present at Advanced Therapies 2023 conference

February 13, 2023 | proactiveinvestors.com

ReNeuron Group’s investment potential ‘remains intact’, 2024 cash runway secured, says Liberum

January 19, 2023 | marketwatch.com

ReNeuron Group Cuts 40% of Staff, Cash Extended into 2024

January 5, 2023 | marketwatch.com

Retinitis Pigmentosa (Retinitis) Market Massive Growth Strikes Due To Technological Innovation During 2023-2028

See More Headlines

Receive RENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/20/2020
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: LON:RENE
CUSIP: N/A
CIK: N/A
Web: www.reneuron.com
Phone: +44-20-38198400
Fax: N/A
Employees: 26
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 0.47
P/E Growth: N/A
Net Income: £-5,070,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -106.77%
Return on Assets: -37.91%

Debt

Debt-to-Equity Ratio: 14.25
Current Ratio: 1.51
Quick Ratio: 2.02

Sales & Book Value

Annual Sales: £783,000.00
Price / Sales: 2.46
Cash Flow: GBX 5.55 per share
Price / Cash Flow: 0.61
Book Value: GBX 4 per share
Price / Book: 0.84

Miscellaneous

Outstanding Shares: 57,170,000
Free Float: N/A
Market Cap: £1.93 million
Optionable: Not Optionable
Beta: 0.69

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Iain Gladstone Ross B.Sc. (Age 70)
BSc (Hons), C.DIR, CH.D, Executive Chairman
Comp: $430k
Mr. John Michael Hawkins A.C.A. (Age 58)
Company Secretary, CFO & Director
Comp: $192.91k
Dr. John David Sinden B.A. (Age 73)
BA, M.A., MA, Ph.D., Co-Founder
Comp: $103k
Ms. Suzanne Hancock
Chief Operations Officer
Dr. Randolph Corteling Ph.D.
Chief Scientific Officer
Mr. Simon Dew
Chief Business Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

RENE Stock Analysis - Frequently Asked Questions

How have RENE shares performed in 2024?: ReNeuron Group's stock was trading at GBX 3.50 at the start of the year. Since then, RENE stock has decreased by 3.6% and is now trading at GBX 3.38.
View the best growth stocks for 2024 here.
How were ReNeuron Group's earnings last quarter?: ReNeuron Group plc (LON:RENE) posted its earnings results on Monday, July, 20th. The company reported ($35.90) EPS for the quarter, topping the consensus estimate of ($50.20) by $14.30.
What other stocks do shareholders of ReNeuron Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR), Sirius Minerals (SXX), Collagen Solutions plc (COS.L) (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).
How do I buy shares of ReNeuron Group?: Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:RENE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial